AXSOME THERAPEUTICS, INC. (AXSM) Spending and interest coverage
- R&D / revenue · 12 months: Value 24.19%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 12.42%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 24.19% | Research and development expense / revenue. Period ending 2026-06-30. $187.86M ÷ $776.57M × 100 ≈ 24.19% |
| Stock-based compensation / revenue · 12 months | 12.42% | Share-based compensation / revenue. Period ending 2026-06-30. $96.42M ÷ $776.57M × 100 ≈ 12.42% |
| Interest coverage · 12 months | (m) | Operating income ÷ reported interest expense. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 187.86M USD | Research and Development Expense |
| Revenue | 776.57M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 96.42M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -186.07M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | -12.88M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $187.86M | $776.57M | $96.42M | $-186.07M | $-12.88M | 24.19% | 12.42% | (m) | Reported |
| 2026-03-31 | $191.17M | $708.24M | $93.88M | $-173.14M | $-18.09M | 26.99% | 13.26% | (m) | Reported |
| 2025-12-31 | $183.28M | $638.50M | $93.75M | $-166.76M | $-15.93M | 28.70% | 14.68% | (m) | Reported |
| 2025-09-30 | $189.49M | $561.26M | $93.01M | $-212.42M | $-18.15M | 33.76% | 16.57% | (m) | Reported |
| 2025-06-30 | $194.72M | $495.03M | $91.56M | $-228.94M | $-20.44M | 39.33% | 18.50% | (m) | Reported |
| 2025-03-31 | $195.03M | $432.16M | $88.34M | $-270.27M | $-21.43M | 45.13% | 20.44% | (m) | Reported |
| 2024-12-31 | $187.08M | $385.69M | $85.22M | $-280.56M | $-21.58M | 48.50% | 22.09% | (m) | Reported |
| 2024-09-30 | $162.87M | $338.46M | $82.15M | $-306.22M | (m) | 48.12% | 24.27% | (m) | (m) |
| 2024-06-30 | $146.25M | $291.49M | $75.33M | $-305.71M | (m) | 50.17% | 25.84% | (m) | (m) |
| 2024-03-31 | $116.98M | $251.02M | $69.87M | $-292.73M | (m) | 46.60% | 27.83% | (m) | (m) |
| 2023-12-31 | $97.94M | $270.60M | $62.62M | $-231.82M | (m) | 36.20% | 23.14% | (m) | (m) |
| 2023-09-30 | $81.83M | $223.44M | $54.47M | $-193.47M | (m) | 36.62% | 24.38% | (m) | (m) |
| 2023-06-30 | $67.94M | $182.49M | $48.83M | $-173.76M | (m) | 37.23% | 26.76% | (m) | (m) |
| 2023-03-31 | $63.16M | $144.61M | $43.07M | $-147.88M | (m) | 43.67% | 29.78% | (m) | (m) |
| 2022-12-31 | $57.95M | $50.04M | $37.73M | $-179.80M | (m) | 115.81% | 75.40% | (m) | (m) |
| 2022-09-30 | $57.04M | (m) | $32.85M | $-152.49M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $55.34M | (m) | $29.37M | $-143.49M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $54.05M | (m) | $24.67M | $-135.15M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $58.06M | (m) | $20.80M | $-124.71M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $61.66M | (m) | $20.52M | $-119.84M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $63.28M | (m) | $17.66M | $-107.56M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $59.32M | (m) | $16.35M | $-94.49M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $70.24M | (m) | $14.76M | $-99.14M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $72.07M | (m) | $11.96M | $-95.83M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $73.11M | (m) | $10.25M | $-93.65M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $73.57M | (m) | $6.99M | $-89.32M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $53.65M | (m) | $6.12M | $-67.25M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $41.59M | (m) | $3.65M | $-52.27M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $31.80M | (m) | $2.89M | $-41.56M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $26.35M | (m) | $2.48M | $-36.10M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $23.50M | (m) | $1.75M | $-32.85M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $20.84M | (m) | $1.94M | $-29.84M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $19.27M | (m) | $1.93M | $-27.89M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $18.72M | (m) | $1.94M | $-26.66M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $19.96M | (m) | $2.07M | $-27.16M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $21.27M | (m) | $1.97M | $-28.35M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $22.37M | (m) | $2.04M | $-29.26M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $22.66M | (m) | $2.04M | $-29.33M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $21.20M | (m) | $2.03M | $-27.54M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $6.78M | (m) | $803.28K | $-9.20M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $4.28M | (m) | $376.81K | $-5.67M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |